Literature DB >> 27247323

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.

Agnès Charpentier1, Aurélien Lebreton2, Antoine Rauch3, Anne Bauters4, Nathalie Trillot4, Oliver Nibourel5, Véronique Tintillier4, Mathieu Wemeau6, Jean-Loup Demory7, Claude Preudhomme5, Brigitte Jude3, Thomas Lecompte8, Nathalie Cambier9, Sophie Susen10.   

Abstract

Entities:  

Keywords:  CALR; JAK2; chronic myeloproliferative disorders; microparticles; thrombosis

Mesh：

Substances：

Year:  2016        PMID： 27247323      PMCID： PMC5060032          DOI： 10.3324/haematol.2016.144279

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.

Authors:  Jérôme Duchemin; Valérie Ugo; Jean-Christophe Ianotto; Lydie Lecucq; Bernard Mercier; Jean-François Abgrall
Journal:  Thromb Res       Date:  2010-07-24       Impact factor: 3.944

Review 2.  Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles.

Authors:  E van der Pol; A N Böing; E L Gool; R Nieuwland
Journal:  J Thromb Haemost       Date:  2015-12-29       Impact factor: 5.824

3.  Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

Authors:  Tiziano Barbui; Guido Finazzi; Alessandra Carobbio; Juergen Thiele; Francesco Passamonti; Elisa Rumi; Marco Ruggeri; Francesco Rodeghiero; Maria Luigia Randi; Irene Bertozzi; Heinz Gisslinger; Veronika Buxhofer-Ausch; Valerio De Stefano; Silvia Betti; Alessandro Rambaldi; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

Review 4.  Revisited role of microparticles in arterial and venous thrombosis.

Authors:  R Lacroix; C Dubois; A S Leroyer; F Sabatier; F Dignat-George
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 5.  Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Authors:  Ayalew Tefferi; Tiziano Barbui
Journal:  Am J Hematol       Date:  2015-02       Impact factor: 10.047

6.  Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop.

Authors:  R Lacroix; C Judicone; M Mooberry; M Boucekine; N S Key; F Dignat-George
Journal:  J Thromb Haemost       Date:  2013-04-02       Impact factor: 5.824

7.  Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.

Authors:  Marijke C Trappenburg; Muriel van Schilfgaarde; Marina Marchetti; Henri M Spronk; Hugo ten Cate; Anja Leyte; Wim E Terpstra; Anna Falanga
Journal:  Haematologica       Date:  2009-06-08       Impact factor: 9.941

8.  Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.

Authors:  Naseema Gangat; Emnet A Wassie; Terra L Lasho; Christy Finke; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani; Alexandra P Wolanskyj; Margherita Maffioli; Rosario Casalone; Francesco Passamonti; Ayalew Tefferi
Journal:  Eur J Haematol       Date:  2014-12-04       Impact factor: 2.997

9.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

10.  JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.

Authors:  Catherine M Hobbs; Harriet Manning; Cavan Bennett; Louella Vasquez; Sonia Severin; Lauren Brain; Alexandra Mazharian; Jose A Guerrero; Juan Li; Nicole Soranzo; Anthony R Green; Steve P Watson; Cedric Ghevaert
Journal:  Blood       Date:  2013-10-01       Impact factor: 22.113
View more
  11 in total

1.  A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?

Authors:  Claire Pluchart; Coralie Barbe; Gael Poitevin; Sandra Audonnet; Philippe Nguyen
Journal:  J Thromb Thrombolysis       Date:  2020-11-28       Impact factor: 2.300

Review 2.  Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.

Authors:  Alexandre Guy; Johanne Poisson; Chloe James
Journal:  Leukemia       Date:  2021-03-03       Impact factor: 11.528

3.  The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms.

Authors:  Mohamed Hussam Aswad; Jarmila Kissova; Petra Ovesna; Lucie Rihova; Miroslav Penka
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 4.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

Review 5.  Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.

Authors:  Cecilia P Marin Oyarzún; Paula G Heller
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 6.  Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy.

Authors:  Alessandro Sgambato; Ilaria Laurenzana; Stefania Trino; Daniela Lamorte; Antonella Caivano; Luciana De Luca
Journal:  Leukemia       Date:  2020-12-09       Impact factor: 11.528

7.  JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles

Authors:  Hilal Hekimoğlu; Selin Fulya Toprak; Selçuk Sözer
Journal:  Turk J Haematol       Date:  2022-01-04       Impact factor: 1.831

8.  Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm.

Authors:  Johanne Poisson; Marion Tanguy; Hortense Davy; Fatoumata Camara; Marie-Belle El Mdawar; Marouane Kheloufi; Tracy Dagher; Cécile Devue; Juliette Lasselin; Aurélie Plessier; Salma Merchant; Olivier Blanc-Brude; Michèle Souyri; Nathalie Mougenot; Florent Dingli; Damarys Loew; Stephane N Hatem; Chloé James; Jean-Luc Villeval; Chantal M Boulanger; Pierre-Emmanuel Rautou
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 9.  The "Vesicular Intelligence" Strategy of Blood Cancers.

Authors:  Dorian Forte; Martina Barone; Francesca Palandri; Lucia Catani
Journal:  Genes (Basel)       Date:  2021-03-13       Impact factor: 4.096

Review 10.  Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.

Authors:  Vikas Bhuria; Conny K Baldauf; Burkhart Schraven; Thomas Fischer
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.